Figure 3.

Addition of anti-PD1 to MAPK and PI3K pathway inhibition does not alter the infiltration and activation/effector status of CTLs. (A) Tumors from mice treated as described in Fig. 2A (n = 4–5 per group) were analyzed by immunohistochemistry for CD3 infiltration on day 3. The black scale bars equal 3 mm and the high magnification inserts are 400 μm squared. Quantification depicted in (B) In the same setup as A and B, tumors were digested and analyzed by flow cytometry for the percentages of (C) IFNγ producing CD8⁺ T cells (D) granzyme B producing CD8⁺ T cells; and (E) CD44^highCD62L^low expressing CD8⁺ T cells.